Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 06/20/11 → 02/23/16 |
Funding
- Pfizer Incorporated: $25,811.83
An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin Administered in Combination with Rituximab Compared to Defined Investigator's Choice Therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymp
- Schuster, Michael (PI)
- Gabig, Theodore (CoPI)
- Lan, Fengshuo (CoPI)
- Richard, Shambavi (PI)
Project: Research